Intravezikální léčba povrchových nádorů močového měchýře // SOLEN

Urologie pro praxi 3/2004

Intravezikální léčba povrchových nádorů močového měchýře

INTRAVESICAL TREATMENT OF SUPERFICIAL BLADDER TUMORS The goal of intravesical therapy is treatment of Tis and prevention of recurrence and progression in superficial bladder tumors. Mitomycin C and adriamycin are the most often used agents in intravesical chemotherapy. They can reduce the early recurrence rate, but have no effect on late recurrences or risk of progression. Intravesical chemotherapy is used in low and intermediate risk tumors. The most often used agent in intravesical immunotherapy is BCG. It is the most effective treatment modality in Tis, is more effective than intravesical chemotherapy and reduces the risk of tumor progression. BCG is the treatment of choice in high risk superficial tumors. Key words: superficial bladder tumors, recurrence, progression, intravesical chemotherapy, intravesical immunotherapy, BCG.